Striking antibody evasion manifested by the Omicron variant

 

Lihong Liu , 

Sho Iketani , 

Yicheng Guo , 

Jasper F-W. Chan , 

Maple Wang , 

Liyuan Liu , 

Yang Luo , 

Hin Chu , 

Yiming Huang , 

Manoj S. Nair , 

Jian Yu , 

Kenn K-H. Chik , 

Terrence T-T. Yuen , 

Chaemin Yoon , 

Kelvin K-W. To , 

Honglin Chen , 

Michael T. Yin , 

Magdalena E. Sobieszczyk , 

Yaoxing Huang , 

Harris H. Wang , 

Zizhang Sheng , 

Kwok-Yung Yuen & 

David D. Ho

doi: https://doi.org/10.1038/d41586-021-03826-3

PDF: https://media.nature.com/original/magazine-assets/d41586-021-03826-3/d41586-021-03826-3.pdf

ADVANCE ARTICLE PREVIEW

This manuscript has been peer reviewed and accepted for publication in Nature and is provided in this format here as a response to the exceptional public-health crisis. This accepted manuscript will continue through the processes of copy editing and formatting to publication of a finalized version of record on nature.com. Please note there may be errors present in this version, which may affect the content, and all legal disclaimers apply.

The Omicron (B.1.1.529) variant of SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) was only recently detected in southern Africa, but its subsequent spread has been extensive, both regionally and globally1. It is expected to become dominant in the coming weeks2, probably due to enhanced transmissibility. A striking feature of this variant is the large number of spike mutations3 that pose a threat to the efficacy of current COVID-19 (coronavirus disease 2019) vaccines and antibody therapies4. This concern is amplified by the findings from our study. We found B.1.1.529 to be markedly resistant to neutralization by serum not only from convalescent patients, but also from individuals vaccinated with one of the four widely used COVID-19 vaccines. Even serum from persons vaccinated and boosted with mRNA-based vaccines exhibited substantially diminished neutralizing activity against B.1.1.529. By evaluating a panel of monoclonal antibodies to all known epitope clusters on the spike protein, we noted that the activity of 17 of the 19 antibodies tested were either abolished or impaired, including ones currently authorized or approved for use in patients. In addition, we also identified four new spike mutations (S371L, N440K, G446S, and Q493R) that confer greater antibody resistance to B.1.1.529. The Omicron variant presents a serious threat to many existing COVID-19 vaccines and therapies, compelling the development of new interventions that anticipate the evolutionary trajectory of SARS-CoV-2.

https://www.nature.com/articles/d41586-021-03826-3